peptic ulcer disease and H. pylori
Most ulcers are H. pylori or NSAID/ASA. Test with a non-serological test (urea breath test, stool antigen, biopsy) after a 2-week PPI and 4-week antibiotic/bismuth washout. First-line: bismuth quadruple therapy (PBMT) × 14 days — recommended by both Canadian and US guidelines and unaffected by clarithromycin resistance. Avoid clarithromycin or levofloxacin unless susceptibility is known. Test of cure for everyone, ≥4 weeks after treatment. Ulcer on NSAID/antiplatelet that must continue → PPI.
who to test
Testing commits to treating — only test if a positive result would be treated.
- peptic ulcer, active or past (including bleeding ulcer — repeat a negative test from the acute bleed later)
- gastric MALT lymphoma
- uninvestigated dyspepsia <60 without alarm features (test-and-treat instead of endoscopy)
- long-term NSAIDs, or starting long-term low-dose ASA
- unexplained iron deficiency anaemia (iron deficiency); immune thrombocytopenia
- gastric cancer prevention: first-degree relative with gastric cancer, prior early gastric cancer resection, gastric premalignant conditions (atrophic gastritis and gastric intestinal metaplasia), immigrants from high-incidence regions
ACG 2024 also tests adult household members of infected patients — not adopted in Canadian guidance.
tests
| test | use | pitfalls |
|---|---|---|
| urea breath test | diagnosis and test of cure | false negative on PPI (stop 2 weeks), antibiotics or bismuth (stop 4 weeks) |
| stool antigen | diagnosis and test of cure | same washouts |
| biopsy (histology, rapid urease) | at endoscopy | false negative during acute bleed and on PPI |
| serology | not for test-and-treat | stays positive for years after cure → can’t show active infection or cure |
H2RAs and antacids don’t affect the tests — use them for symptoms during the washout.
eradication
All regimens 14 days (longer duration → higher eradication). PPI dosed 30–60 min before meals.
| regimen | components | role |
|---|---|---|
| PBMT (bismuth quadruple) | PPI BID + bismuth subsalicylate or subcitrate QID + metronidazole 500 mg TID–QID + tetracycline 500 mg QID | first-line (Toronto, ACG); also first rescue if not used before |
| PAMC (concomitant) | PPI + amoxicillin 1 g + metronidazole 500 mg + clarithromycin 500 mg, all BID | Toronto first-line option; ACG avoids without known clarithromycin susceptibility |
| PPI triple (PAC) | PPI + amoxicillin + clarithromycin | only where clarithromycin resistance <15% or local eradication >85% — rarely true in Canada |
| levofloxacin triple (PAL) | PPI + amoxicillin + levofloxacin | rescue only (not first-line) |
| rifabutin triple | PPI + amoxicillin + rifabutin | ACG first-line option and rescue after PBMT; Toronto restricts to after ≥3 failures |
| vonoprazan + amoxicillin | potassium-competitive acid blocker dual | ACG first-line option; vonoprazan availability in Canada limited |
- Doxycycline is not a substitute for tetracycline.
- Bismuth subsalicylate → avoid with salicylate allergy; black stool and tongue are expected.
- Metronidazole: no alcohol; resistance is overcome by full-dose, 14-day PBMT.
- Don’t reuse clarithromycin or levofloxacin after a regimen containing them fails.
- Penicillin allergy → allergy assessment (most labels are wrong); PBMT contains no penicillin.
- Probiotics don’t improve eradication.
Rescue: PBMT if not used → levofloxacin-based (if susceptible) or rifabutin-based. Susceptibility testing when the choice is unclear.
test of cure
Everyone, ≥4 weeks after therapy, with urea breath test, stool antigen or biopsy; PPI off for 2 weeks first. Not serology.
NSAIDs, ASA and antithrombotics
- Ulcer while on NSAID → stop the NSAID; if it must continue → COX-2 inhibitor + PPI (each alone still carries meaningful rebleed risk after a bleed).
- Low-dose ASA for secondary prevention → continue with a PPI; test and treat H. pylori.
- DAPT, or antiplatelet + anticoagulant, after an ulcer bleed → long-term PPI. Clopidogrel → pantoprazole (antiplatelets).
- Acute bleeding ulcer management → upper GI bleeding.
ulcer follow-up
- Gastric ulcer → biopsy at index endoscopy; repeat endoscopy to confirm healing if malignancy wasn’t excluded.
- PPI once daily for a duration set by the cause; long-term only if NSAID/antithrombotic exposure continues.
- Refractory or recurrent ulcers despite eradication and no NSAIDs → hidden NSAID/ASA use, failed eradication, malignancy, Crohn’s, or Zollinger–Ellison syndrome (multiple or post-bulbar ulcers, diarrhoea, thick folds) → fasting gastrin off PPI.
Prepared 2026-10-28. Not yet verified — check every number against the sources.